Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Brain Behav. 2023 Jul;13(7):e3051. doi: 10.1002/brb3.3051. Epub 2023 Jun 18.
The aim of this study was to investigate the clinical efficacy of exercise intervention in the treatment of patients with Alzheimer's disease (AD) by meta-analysis.
From January 2000 to January 2022, PubMed, Web of Science, Embase, CNKI, and WanFang databases were searched for all studies on the clinical efficacy of exercise intervention in the treatment of AD patients. Stata 17.0 statistical software was used for meta-analysis.
Specifically, data of 983 patients were subjected to meta-analysis, including 463 patients in the control group (conventional drug therapy) and 520 patients in the treatment group (physical exercise on the basis of conventional therapy). The results of meta-analysis showed that Mini-Mental State Examination (MMSE) score and Activities of Daily Living Scale (ADL) score in the treatment group were significantly higher than those in the control group. Further subgroup analysis of exercise intervention >16 weeks found that MMSE and ADL scores in the treatment group were significantly higher than those in the control group. Subgroup analysis of exercise intervention ≤16 weeks demonstrated that MMSE and ADL in the treatment group were higher than those in the control group. In addition, the treatment group had a significant lower Neuropsychiatric Inventory (NPI) score compared with the control group (SMD = -0.76, 95% CI (-1.37, -0.16), p = .013); subgroup analysis showed that the NPI score in the treatment group were lower than that in the control group when exercise intervention was >16 weeks [SMD = -1.01, 95% CI (-1.99, -0.04), p = .042] and ≤16 weeks [SMD = 0.43, 95% CI (-0.82, -0.03), p = .034].
Exercise intervention can improve the neuropsychiatric symptoms, activities of daily living and cognitive function of AD patients, but the improvement is not significant in case of exercise intervention ≤16 weeks.
本研究旨在通过荟萃分析探讨运动干预对阿尔茨海默病（AD）患者的临床疗效。
从 2000 年 1 月至 2022 年 1 月，检索 PubMed、Web of Science、Embase、CNKI 和万方数据库中关于运动干预治疗 AD 患者的临床疗效的所有研究。采用 Stata 17.0 统计软件进行荟萃分析。
共有 983 例患者的数据进行了荟萃分析，其中对照组（常规药物治疗）463 例，治疗组（在常规治疗基础上进行体育锻炼）520 例。荟萃分析结果显示，治疗组的简易精神状态检查（MMSE）评分和日常生活活动量表（ADL）评分明显高于对照组。进一步对运动干预>16 周的亚组分析发现，治疗组的 MMSE 和 ADL 评分明显高于对照组。对运动干预≤16 周的亚组分析显示，治疗组的 MMSE 和 ADL 评分高于对照组。此外，与对照组相比，治疗组的神经精神问卷（NPI）评分显著降低（SMD=-0.76，95%CI（-1.37，-0.16），p=0.013）；亚组分析显示，当运动干预>16 周时，治疗组的 NPI 评分低于对照组[SMD=-1.01，95%CI（-1.99，-0.04），p=0.042]和≤16 周[SMD=0.43，95%CI（-0.82，-0.03），p=0.034]。
运动干预可以改善 AD 患者的神经精神症状、日常生活活动能力和认知功能，但运动干预≤16 周时改善不明显。
